Vixotrigine

Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Na_v1.3 blocker, but was subsequently redefined as a selective peripheral Na_v1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.[4]

Vixotrigine

Clinical data
Other names	Raxatrigine; CNV1014802; GSK-1014802; BIIB 074
Routes of administration	By mouth
ATC code	None
Identifiers
IUPAC name (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
CAS Number	934240-30-9 934240-35-4 (mesylate)
PubChem CID	16046068
ChemSpider	13174481
UNII	QQS4J85K6Y
KEGG	D11179
Chemical and physical data
Formula	C18H19FN2O2
Molar mass	314.360 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
InChI InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1 Key:JESCETIFNOFKEU-SJORKVTESA-N

See also

• List of investigational analgesics

References

1. "CNV1014802". Convergence Pharmaceuticals.
2. McMahon S, Koltzenburg M, Tracey I, Turk DC (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.
3. Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
4. "Vixotrigine - Biogen". Adis Insight. Springer Nature Switzerland AG.

External links

• Vixotrigine - AdisInsight